Home » Clinical Trials » Leukemia » NCT05309733
NCT05309733

A Long-term Follow-up Study of Patients Who Received VOR33

Study Summary

VOR33 long-term follow-up (LTFU) study

Want to learn more about this trial?

Request More Info

Interventions

VOR33GENETIC
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.

Study Locations

FacilityCityStateCountry
University of California San Diego Moores Cancer CenterLa JollaCaliforniaUnited States
Miami Cancer InstituteMiamiFloridaUnited States
National Institutes of Health, Clinical CenterBethesdaMarylandUnited States
Washington University School of Medicine Siteman Cancer CenterSt LouisMissouriUnited States
John Theurer Cancer Center at Hackensack University Medical CenterHackensackNew JerseyUnited States
Icahn School of Medicine at Mount SinaiNew YorkNew YorkUnited States
Columbia University Medical Center - Herbert Irving Comprehensive Cancer CenterNew YorkNew YorkUnited States
Memorial Sloan Kettering Cancer CenterNew YorkNew YorkUnited States
University Hospitals Seidman Cancer CenterClevelandOhioUnited States
Fred Hutchinson Cancer Research CenterSeattleWashingtonUnited States
Hôpital Maisonneuve-RosemontMontrealQuebecCanada

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026